Background: Mutant peptides presented by cancer cells are superior vaccine candidates than self peptides. The\nefficacy of mutant K-Ras, P53 and EGFR (Epidermal Growth Factor Receptor) peptides have been tested as cancer\nvaccines in pancreatic, colorectal, and lung cancers. The immunogenicity of EGFR Del19 mutations, frequent in\nChinese lung adenocarcinoma patients, remains unclear.\nResults: We predicted the HLA binding epitopes of Del19 mutations of EGFR in Chinese lung adenocarcinoma\npatients with NetMHC software. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the EGFRreactive\nIgG in lung cancer patients. Del19 mutations may be presented by multiple HLA Class I molecules, with\ndelE746_A750 presented by 37.5% of Chinese population. For HLA Class II molecules, Del19 mutations of EGFR may\nbe presented by multiple HLA-DRB1 molecules, with delE746_A750 presented by 58.1% of Chinese population.\nSerum reactivity to wild type EGFR protein was significantly higher in patients with Del19 EGFR mutations than\nthose with EGFR L858R point mutation or with EGFR wild type genotype.\nConclusions: These findings suggest that Del19 mutations of EGFR, with an estimated frequency of 40% in Chinese\nlung adenocarcinoma patients, may serve as unique targets for immunotherapy in Chinese lung cancer patients.
Loading....